Central nervous system late effects: A new frontier? (Commentary on Kamdar et al., page 454)

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 355-356

  Waber, Deborah P ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FOLIC ACID; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ATTENTION DEFICIT DISORDER; BRAIN DAMAGE; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; FOLATE METABOLISM; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; INTELLECTUAL IMPAIRMENT; LEARNING DISORDER; NOTE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SEIZURE;

ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; FEMALE; FOLIC ACID; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 79960170341     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23206     Document Type: Note

References (10)

1. Waber DP, Mullenix PJ. Acute lymphoblastic leukemia. In: Yeates KO, Ris MD, Taylor HG, editors. Pediatric neuropsychology: Research, theory, and practice. New York: Guilford; 2000. pp. 300-319.
2. Waber DP, Turek J, Catania L, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: Findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 2007; 25: 4914-4921.
3. Waber DP, Silverman LB, Catania L, et al. Outcomes of a randomized trial of hyperfractonated cranial radiation therapy (18Gy) for treatment of high-risk acute lymphoblastic leukemia: Therapeutic efficacy and neurotoxicity. J Clin Oncol 2004; 22: 2701-2707.
4. Kadan-Lottick NS, Brouwers P, Breiger D, et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2009; 27: 5986-5992.
5. Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009; 114: 1746-1752.
6. Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 1991; 9: 1348-1356.
7. Quinn CT, Griener JC, Bottiglieri T, et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997; 15: 2800-2806.
8. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084-3091.
9. Krajinovic M, Robaey P, Chiasson S, et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 2005; 6: 293-302.
10. Krull KR, Brouwers P, Jain N, et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr 2008; 152: 101-105.